search
Back to results

Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Mali

Primary Purpose

Malaria

Status
Completed
Phase
Not Applicable
Locations
Mali
Study Type
Interventional
Intervention
Lipid-based Nutrient Supplement (LNS)
Seasonal malaria chemoprevention
Sponsored by
Alliance for International Medical Action
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Malaria focused on measuring Seasonal malaria chemoprevention, Lipid-based nutrient supplement, Children, Mali

Eligibility Criteria

6 Months - 59 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Being between 6 and 59 months old
  • Resident in the study area
  • Signed informed consent of the mother or the child's guardian

Exclusion Criteria:

  • Children allergic to milk, peanuts, sulfadoxine-pyrimethamine or amodiaquine

Sites / Locations

  • Amcp/Alima

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

SMC and LNS (intervention group)

SMC only (control group)

Arm Description

Children included in the 9 health areas of the intervention group receiving both lipid-based nutrient supplement and seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine

Children included in the 9 health areas of the control group receiving seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine

Outcomes

Primary Outcome Measures

Confirmed malaria case
Malaria case is confirmed by a positive malaria rapid diagnostic test. This outcome will be defined as the occurrence of at least one confirmed malaria case from the 2nd through the 4th round of SMC distribution.

Secondary Outcome Measures

Fever case
Fever case is defined by an axillary temperature greater than 37.5⁰C measured by electronic thermometer or notion fever within 48 hours. This outcome will be defined as the occurrence of at least one fever case from the 2nd through the 4th round of SMC distribution.
Global acute malnutrition case
Global acute malnutrition is defined by MUAC <125mm (orange or red color MUAC) and/or bilateral edema. This outcome will be defined as the occurrence of at least one global acute malnutrition case from the 2nd through the 4th round of SMC distribution.
Moderate acute malnutrition case
Moderate acute malnutrition is defined by MUAC between 115-124mm (orange color MUAC). This outcome will be defined as the occurrence of at least one moderate acute malnutrition case from the 2nd through the 4th round of SMC distribution.
Severe acute malnutrition case
Severe acute malnutrition is defined by MUAC <115mm (red color MUAC) and/or bilateral edema. This outcome will be defined as the occurrence of at least one severe acute malnutrition case from the 2nd through the 4th round of SMC distribution.
Medical referral case
This outcome will be defined as the occurrence of at least one illness of sufficient severity to warrant referral to the nearest medical structure for evaluation from the 2nd through the 4th round of SMC distribution.

Full Information

First Posted
January 17, 2017
Last Updated
January 25, 2017
Sponsor
Alliance for International Medical Action
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France, Alliance médicale contre le paludisme, Mali, Programme national de lutte contre le paludisme, Mali, United States Agency for International Development (USAID), European commission for humanitarian office, Ministry of health, Mali
search

1. Study Identification

Unique Protocol Identification Number
NCT03035305
Brief Title
Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Mali
Official Title
Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Kolokani Circle, Koulikoro Region, Mali, August-November 2016: Interventional Matched-pair Clustered Cohort
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
August 2016 (Actual)
Primary Completion Date
November 2016 (Actual)
Study Completion Date
November 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alliance for International Medical Action
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France, Alliance médicale contre le paludisme, Mali, Programme national de lutte contre le paludisme, Mali, United States Agency for International Development (USAID), European commission for humanitarian office, Ministry of health, Mali

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
SMC LNS Mali is a interventional matched-pair clustered cohort carried out between August and November 2017 in 18 health areas in Kolokani Circle, Koulikoro region, Mali. The objective of this study is to determine whether the association SMC and LNS reduces the number of confirmed malaria cases among children 6-59 months during the monthly SMC distribution sessions.
Detailed Description
Main objective: To compare confirmed cases of malaria among children aged 6-59 months between the group receiving SMC combined with LNS (intervention group) and the group receiving only SMC (control group) during the monthly SMC distribution sessions (4 rounds) Secondary objectives: To compare among children aged 6-59 months between two groups Fever cases Acute malnutrition cases (global, moderate and severe) Medical referral cases and their reasons Study site: The study is conducted in 18 health areas in Kolokani Circle, Koulikoro region, Mali. Each group (intervention and control groups) is composed of 9 health areas. Number of participants: Between 17500 and 22000 in each group (estimation)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malaria
Keywords
Seasonal malaria chemoprevention, Lipid-based nutrient supplement, Children, Mali

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
36717 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SMC and LNS (intervention group)
Arm Type
Experimental
Arm Description
Children included in the 9 health areas of the intervention group receiving both lipid-based nutrient supplement and seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine
Arm Title
SMC only (control group)
Arm Type
Other
Arm Description
Children included in the 9 health areas of the control group receiving seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine
Intervention Type
Dietary Supplement
Intervention Name(s)
Lipid-based Nutrient Supplement (LNS)
Intervention Description
For each round of SMC distribution (total of 4 rounds): For children aged 6-11 months: 15 sachets/month or 50g every two days for 4 weeks For children aged 12-59 months: 21 sachets/month or 50g per day for 3 weeks
Intervention Type
Drug
Intervention Name(s)
Seasonal malaria chemoprevention
Other Intervention Name(s)
Sulfadoxine-pyrimethamine plus amodiaquine
Intervention Description
For each round of SMC distribution (total of 4 rounds): For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine
Primary Outcome Measure Information:
Title
Confirmed malaria case
Description
Malaria case is confirmed by a positive malaria rapid diagnostic test. This outcome will be defined as the occurrence of at least one confirmed malaria case from the 2nd through the 4th round of SMC distribution.
Time Frame
From the 2nd round of SMC distribution (4 weeks after the date of inclusion) to the 4th round of SMC distribution (12 weeks after the date of inclusion), assessed up to 8 weeks
Secondary Outcome Measure Information:
Title
Fever case
Description
Fever case is defined by an axillary temperature greater than 37.5⁰C measured by electronic thermometer or notion fever within 48 hours. This outcome will be defined as the occurrence of at least one fever case from the 2nd through the 4th round of SMC distribution.
Time Frame
From the 2nd round of SMC distribution (4 weeks after the date of inclusion) to the 4th round of SMC distribution (12 weeks after the date of inclusion), assessed up to 8 weeks
Title
Global acute malnutrition case
Description
Global acute malnutrition is defined by MUAC <125mm (orange or red color MUAC) and/or bilateral edema. This outcome will be defined as the occurrence of at least one global acute malnutrition case from the 2nd through the 4th round of SMC distribution.
Time Frame
From the 2nd round of SMC distribution (4 weeks after the date of inclusion) to the 4th round of SMC distribution (12 weeks after the date of inclusion), assessed up to 8 weeks
Title
Moderate acute malnutrition case
Description
Moderate acute malnutrition is defined by MUAC between 115-124mm (orange color MUAC). This outcome will be defined as the occurrence of at least one moderate acute malnutrition case from the 2nd through the 4th round of SMC distribution.
Time Frame
From the 2nd round of SMC distribution (4 weeks after the date of inclusion) to the 4th round of SMC distribution (12 weeks after the date of inclusion), assessed up to 8 weeks
Title
Severe acute malnutrition case
Description
Severe acute malnutrition is defined by MUAC <115mm (red color MUAC) and/or bilateral edema. This outcome will be defined as the occurrence of at least one severe acute malnutrition case from the 2nd through the 4th round of SMC distribution.
Time Frame
From the 2nd round of SMC distribution (4 weeks after the date of inclusion) to the 4th round of SMC distribution (12 weeks after the date of inclusion), assessed up to 8 weeks
Title
Medical referral case
Description
This outcome will be defined as the occurrence of at least one illness of sufficient severity to warrant referral to the nearest medical structure for evaluation from the 2nd through the 4th round of SMC distribution.
Time Frame
From the 2nd round of SMC distribution (4 weeks after the date of inclusion) to the 4th round of SMC distribution (12 weeks after the date of inclusion), assessed up to 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
59 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Being between 6 and 59 months old Resident in the study area Signed informed consent of the mother or the child's guardian Exclusion Criteria: Children allergic to milk, peanuts, sulfadoxine-pyrimethamine or amodiaquine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susan Shepherd, MD
Organizational Affiliation
The Alliance for International Medical Action (ALIMA)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Renaud Becquet, PhD
Organizational Affiliation
Inserm U1219 Bordeaux Population Health Center, University of Bordeaux
Official's Role
Principal Investigator
Facility Information:
Facility Name
Amcp/Alima
City
Kolokani Circle
State/Province
Koulikoro region
Country
Mali

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Mali

We'll reach out to this number within 24 hrs